Genomic sequencing analysis of 733 HER2-amplified Main and metastatic breast tumours unveiled important enrichment of mutations that activate RAS–MAPK signalling in Sophisticated tumours addressed with prior anti-HER2 therapies121. These mutations, which includes NF1 and HER2 activating mutations, add to resistance to tucatinib and neratinib. The sort of tissue exactly where https://www.directivepublications.org/journal-of-clinical-breast-cancer/